Seite 1 von 1
Neuester Beitrag: 30.04.20 16:56
|Eröffnet am:||15.02.16 14:03||von: musicus1||Anzahl Beiträge:||23|
|Neuester Beitrag:||30.04.20 16:56||von: Vassago||Leser gesamt:||4.246|
TXMD meldet Zahlen für Q2/19
Anschuldigungen der SEC
"As detailed in the SEC’s order, on June 15, 2017, one day after a publicly-announced meeting with the FDA about a new drug approval, TherapeuticsMD sent private messages to sell-side analysts describing the meeting as “very positive and productive.” TherapeuticsMD’s stock price closed up 19.4 percent on heavy trading volume the next day. At that time, the company had not issued a press release or made any other market-wide disclosure about the meeting."
Details zum Offering
Zahlen für Q4/19
"The company projects that product net revenue for 2020 will be between $90 million to $110 million. The company projects that product net revenue during the second half of the year will be significantly larger than the first half with the majority of 2020 product net revenue coming from ANNOVERA and IMVEXXY. The company anticipates high deductible and annual copay resets will impact first quarter of 2020 revenue for its menopause products and expects first quarter 2020 product net revenue to come in below fourth quarter 2019 product net revenue."